ROIVANT SCIENCES LTD. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect the Board of Directors' three nominees for Class III Director to serve for a three-year term: Ilan Oren

ROIVANT SCIENCES LTD.’s own tally for this item (“Elect Director: Ilan Oren”): 409,647,664 for, 195,587,109 withheld, per its Form 8-K filed September 16, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) Shareholders re-elected the individuals named below to serve as Class III directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2027, and until their successors are duly elected and qualified, or until su…”
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 33,541,414 for, 49,038,153 withheld, 19,247,111 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: To elect the Board of Directors' three nominees for Class III Director to serve for a three-year term: James C. Momtazee

ROIVANT SCIENCES LTD.’s own tally for this item (“Elect Director: James C. Momtazee”): 457,800,746 for, 147,434,027 withheld, per its Form 8-K filed September 16, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) Shareholders re-elected the individuals named below to serve as Class III directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2027, and until their successors are duly elected and qualified, or until su…”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 64,309,606 for, 36,886,728 withheld, 630,344 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: To elect the Board of Directors' three nominees for Class III Director to serve for a three-year term: Mayukh Sukhatme

ROIVANT SCIENCES LTD.’s own tally for this item (“Elect Director: Dr. Mayukh Sukhatme”): 602,544,381 for, 2,690,392 withheld, per its Form 8-K filed September 16, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) Shareholders re-elected the individuals named below to serve as Class III directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2027, and until their successors are duly elected and qualified, or until su…”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 100,868,553 for, 269,294 withheld, 688,831 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: To cast a non-binding, advisory vote to approve the compensation of our named executive officers.

ROIVANT SCIENCES LTD.’s own tally for this item (“3. On a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures”): 540,184,951 for, 64,461,892 against — passed, per its Form 8-K filed September 16, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) Shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of ROIVANT SCIENCES LTD.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on pay” (2 managers, 276,530 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 71 managers: 72,581,077 for, 29,170,785 against, 74,815 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 209 managers: 331,061,220 for, 56,644,283 against, 735,828 abstained, 240 not voted, 481,375 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers every:

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 68 managers: 32,386 for, 74,815 abstained, 101,172,411 1 year, 198,600 3 year, 105,000 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 197 managers: 3,191,305 for, 9,900 against, 734,263 abstained, 240 not voted, 297,018,410 1 year, 5,710,472 unknown, 2,128,881 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Roivant's independent registered public accounting firm for Roivant's fiscal year ending March 31, 2025, to appoint Ernst & Young LLP as auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for Roivant's fiscal year ending March 31, 2025, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as Roivant's auditor for Roivant's fiscal year ending March 31, 2025.

ROIVANT SCIENCES LTD.’s own tally for this item (“2. The appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2025, and to appoint EY as the Company's auditor for statutory p”): 679,096,310 for, 759,669 against — passed, per its Form 8-K filed September 16, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) Shareholders ratified the appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2025, and to appoint EY as the Company's auditor for statutory purposes under the Bermuda Companies Act 1981, as amended…”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the votes cast (“majority of the votes cast”).

The 73 asset managers below reported 101,756,505 for, 74,815 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.